Early CMV DNAemia during letermovir prophylaxis predicts lower risk of late CMV infection and is associated with enhanced T-cell immunity after alloHSCT
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-27490-z
Abstract: CMV-specific immune monitoring may support individualized risk stratification after allogeneic hematopoietic stem cell transplantation (alloHSCT), but its role in the era of letermovir prophylaxis remains unclear. In this prospective single-center study, 45 CMV-seropositive alloHSCT recipients… read more here.
Keywords: letermovir prophylaxis; cmv; early cmv; cell ... See more keywords
Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022008047
Abstract: Key Points • Letermovir is a highly effective and well-tolerated CMV prophylaxis in adult CBT recipients.• Extended CMV prophylaxis for at least 6 months is beneficial in adult CBT recipients, but optimal prophylaxis duration remains… read more here.
Keywords: extended duration; letermovir prophylaxis; duration letermovir; prophylaxis ... See more keywords
Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15848
Abstract: Background/Aim: Cytomegalovirus (CMV) infection is one of the major causes of morbidity following hematopoietic cell transplantation (HCT). Allogeneic HCT (allo-HCT) recipients are at the highest risk of clinically significant CMV reactivation. While letermovir has been… read more here.
Keywords: infection; hct; group; letermovir prophylaxis ... See more keywords